<DOC>
	<DOCNO>NCT00434109</DOCNO>
	<brief_summary>The purpose study decide medicine slow growth new blood vessel give embolization procedure prevent delay new growth blood vessel tumor .</brief_summary>
	<brief_title>Phase II Study Sunitinib Malate Following Hepatic Artery Embolization</brief_title>
	<detailed_description>This single-center , open-label , non-randomized , prospective phase II trial . Sutent treatment continue disease progression , excessive toxicity ( determined treat physician primary investigator ) , maximum eight cycle , whichever duration shorter .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Welldifferentiated metastatic carcinoid tumor pancreatic endocrine tumor measurable liver metastasis . Resolution acute toxic effect prior chemotherapy radiotherapy surgical procedure National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 3.0 grade less equal 1 . Adequate organ function define follow criterion : 1 . Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase [ SGOT ] ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase [ SGPT ] ) less equal 2.5 x local laboratory upper limit normal ( ULN ) , AST ALT less equal 5 x ULN liver function abnormality due underlying malignancy 2 . Total serum bilirubin less equal 1.5 x ULN 3 . Absolute neutrophil count ( ANC ) great equal 1500/microL 4 . Platelets great equal 100,000/microL 5 . Hemoglobin great equal 9.0 g/dL 6 . Serum calcium less equal 12.0 mg/dL 7 . Serum creatinine less equal 1.5 x ULN 8 . Prothrombin activate partial thromboplastin time ( PT aPTT ) less equal 1.5 x ULN Eastern Cooperative Oncology Group ( ECOG ) Performance Status less equal 2 Informed Consent : Patients must aware nature his/her disease process must willingly give consent inform experimental nature therapy , alternative , potential benefit , sideeffects , risk discomfort . Major surgery radiation therapy within 4 week start study treatment . Prior hepatic artery embolization chemoembolization . Prior treatment tyrosine kinase inhibitor vascular endothelial growth factor ( VEGF ) inhibitor . NCI CTCAE grade 3 hemorrhage within 4 week start study treatment . History known brain metastasis , spinal cord compression , carcinomatous meningitis , evidence symptomatic brain leptomeningeal disease screen compute tomography ( CT ) magnetic Resonance imaging ( MRI ) scan . Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Ongoing cardiac dysrhythmias NCI CTCAE grade great equal 2 . Prolonged correct QT ( QTc ) interval baseline electrocardiogram ( EKG ) . Hypertension control medication ( &gt; 150/100 mm Hg despite optimal medical therapy ) . Preexisting thyroid abnormality thyroid function maintain normal range medication . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection Concurrent treatment another clinical trial . Supportive care trial nontreatment trial , e.g . Quality Life ( QOL ) , allow . Concomitant use ketoconazole agent know induce CYP3A4 . Concomitant use theophylline phenobarbital and/or agent metabolize cytochrome P450 system . Ongoing treatment therapeutic dos Coumadin ( low dose Coumadin 2 mg mouth ( po ) daily thrombo prophylaxis allow ) . Pregnancy breastfeed . Female participant must surgically sterile postmenopausal , must agree use effective contraception period therapy . Female participant reproductive potential must negative pregnancy test ( serum urine ) prior enrollment . Male participant must surgically sterile must agree use effective contraception period therapy . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Carcinoid</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Neuroendocrine</keyword>
	<keyword>Tumors</keyword>
	<keyword>Hepatic</keyword>
	<keyword>Artery</keyword>
	<keyword>Embolization</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Malate</keyword>
	<keyword>Sutent</keyword>
	<keyword>Tyrosine</keyword>
	<keyword>Kinase</keyword>
	<keyword>Inhibitor</keyword>
</DOC>